pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Biosimilar · news · pharmadog
← back to Biosimilar
News · Biosimilar
22
stories
22h
Regeneron to challenge Ipsen as FDA clears bone disease drug
biopharma dive
1d
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
1d
Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
fiercebiotech
2d
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
3d
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
biospace
4d
STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more
stat
16d
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
18d
Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity
biospace
21d
FDA drafts guidance on container closure systems, device constituents for biosimilars
raps
22d
Recon: FDA adcomm votes against Capricor’s DMD drug; Cytokinetics gets UK approval, NICE backing for heart drug
raps
22d
Euro Roundup: EFPIA pushes for shorter trial approval times in EU Biotech Act
raps
22d
FDA updates product-specific guidelines for injectable peptides
raps
22d
Researchers concerned by underutilization of accelerated approval in oncology
raps
22d
FDA unveils FY 2027 user fee rates
raps
29d
Euro Roundup: EMA seeks feedback on planned changes to guidance on biosimilar efficacy studies
raps
Jul 2, 26
Sandoz launches direct-to-consumer platform with growth disorder drug
endpoints
Jun 15, 26
Medicare drug price rule may target under-the-skin Keytruda and Opdivo
biopharma dive
Jun 15, 26
J&J multiple myeloma drug gains edge in earlier stage disease
biopharma dive
Jun 8, 26
J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
biopharma dive
Apr 27, 26
Sun Pharma to buy Organon for $11.75B in major portfolio expansion
endpoints
Apr 23, 26
Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
biopharma dive
Apr 23, 26
Amneal to buy a biosimilar company; Samsung Bio workers protest
endpoints
